NICE recommends Boehringer’s nintedanib plus docetaxel to treat NSCLC

Boehringer Ingelheim has announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended company’s Vargatef (nintedanib) in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) within t…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news